iBio stockholders approve increase in authorized shares to 500 million from 275 million
At its October 14, 2026 annual meeting, iBio stockholders approved raising authorized common stock from 275 million to 500 million shares, effective October 16, 2026 upon filing with Delaware. They also approved an amendment to the 2023 Omnibus Incentive Plan that adds shares to the plan each year, and re-elected two Class III directors. A larger pool of authorized shares gives the company room to issue more stock, which could dilute existing holders.
Key points
- Authorized common stock rose from 275,000,000 to 500,000,000 shares; Certificate of Amendment filed October 16, 2026.
- Authorized share increase approved with 45,730,093 votes for and 2,052,563 against.
- Plan amendment approved with 27,693,575 votes for and 8,263,100 against; plan share reserve rises each January 1 from 2027 through 2033.
- Two Class III directors, William Clark and Gary Sender, were elected to terms expiring at the 2029 annual meeting.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.